Ocugen, Inc.
OCGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $461.2M
$1.36
▲ +0.74%
P/E
-10.48
Mkt Cap
$461.2M
52-Wk Range
$1.01–$2.73
52-Week Range
$1.01 - $2.73
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+6.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying OCGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of -$0.07 vs -$0.05 consensus (-31.3% surprise). Revenue of $1.5M vs $888.8K expected (+67.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-31.3%
Revenue trend · last 2Q
—
+8%
Q1 26
Q2 26
$1.5M
$1.5M
Margins · last 2Q
Gross
100.0%
Profit
-1671.8%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Canaccord · May 27, 2026
vs Industry
How OCGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.